🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

❕🔬 A new CAR-T-cell therapy that tricks the tumour could increase treatment efficiency in B-cell Acute Lymphoblastic Leukaemia #ALL 👉 carrerasresearch.org/en/news/a-new-… 📋 Results published in @BloodJournal by researchers from Menendez Lab and Hospital Universitario 12 de Octubre - CNIO Stop Cancer

Great collaboration with the Cancer Immunotherapy group lead by Dr Alvarez Vallina CNIO Stop Cancer Hospital Universitario 12 de Octubre as well as Orfao Lab Hospital Clínic and many others. Great leadership by Aïda Falgàs Clara Bueno!!! Thanks all for making it possible

A privilege to be part of this study published in @BloodJournal and led by Aïda Falgàs Clara Bueno Menendez Lab Josep Carreras Leukaemia Research Institute (IJC) to develop a CAR-T strategy that tricks B-ALL with molecular decoys. Thanks to RLázaro-Gorines and cancer immunotherapy team CNIO Stop Cancer Hospital Universitario 12 de Octubre

Thrilled to share our paper published in Blood Journal! Josep Carreras Leukaemia Research Institute (IJC) CNIO Stop Cancer Hospital Clínic Hospital Universitario 12 de Octubre Huge thanks to everyone involved in this work! Check out the full paper! lnkd.in/dE_82UpY #Immunotherapy #CAR19 #BALL

Our work has just been published in Cancer Research! We found that ammonia produced by cancer cells in the TME suppresses NK and T cells, which may reduce the efficacy of immunotherapies, including CAR-NK and CAR-T cell therapies Cancer Research AACR aacrjournals.org/cancerres/arti…

🚀 Excited to share our latest in Journal for ImmunoTherapy of Cancer : CD22 CAR-T cells secreting CD19 engagers (CAR-STAb-T) show superior control of B-ALL—even when CD19 is lost. A promising option for relapsed patients. Huge thanks to all collaborators! 🙌 #CancerStabbers jitc.bmj.com/content/13/4/e…

Happy to share our latest work Menendez Lab Clara Bueno Aïda Falgàs Josep Carreras Leukaemia Research Institute (IJC) in collaboration with the Luis Álvarez-Vallina Lab at CNIO Stop Cancer and Hospital Universitario 12 de Octubre on new CD22 and CD19 T cell redirecting strategies spanning CAR &T-cell engagers (STabs). pubmed.ncbi.nlm.nih.gov/40306957/

Dr. Olaf Heidenreich (PrinsesMáximaCentrum) will deliver a special #InvitedLecture at our Institute — don’t miss it! 🎙️ "AML: a balancing act between proliferation differentiation and self-renewal" 🗓️Wednesday, 7 May 2025, 3pm CEST 📍IJC Auditorium 🔗 Join online at

⚗️Workshop: Harmonizing In Vivo Models of Immunotherapy was a great success! Great energy and thoughtful discussion at the Workshop in Bergen, where 53 participants explored how #invivomodels can drive progress in #immunotherapy. 👏 Huge thanks to organizers #COST

It was great to be part of the Workshop and learn so many new models to test immunotherapies in vivo! #immunomodel #cost

We thank ACIR for highlighting our paper, 'CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukaemia progression' published in Journal for ImmunoTherapy of Cancer, co-authored by Javier Arroyo Hospital Universitario 12 de Octubre CNIO Stop Cancer & Aïda Falgàs Josep Carreras Leukaemia Research Institute (IJC)

🔬 Researchers led by Aïda Falgàs (Menendez Lab) and Javier Arroyo (Hospital Universitario 12 de Octubre CNIO Stop Cancer) have developed a novel dual-action CAR-T therapy for B-ALL, combining CD22 targeting with a secreted CD19 T-cell engager. ✅ This new approach enhances immune response and reduces relapse

Gracias Fundación Fero y Fundación Aladina x apoyar a nuestro equipo Carla Panisello Clara Bueno a llevar este trabajo a clinica

It's such a great honor to be part of this team! Happy that our effort is being valued by Fundación Aladina and Fundación Fero ! We will keep working for the fight against paediatric cancer! 👩🏼‍🔬👩🏼‍🔬👩🏼‍🔬 Menendez Lab Clara Bueno

🔵 El Dr. Pablo Menéndez recibe la Beca Fundación Fero-Fundación Aladina en cáncer pediátrico 🔬 Gracias a esta ayuda el Menendez Lab trabajará en el desarrollo de una inmunoterapia más efectiva y menos tóxica, reforzada con células CAR-T, para tratar sarcomas pediátricos. ➡️

Few weeks ago I visited the Hans Clevers group in PrinsesMáximaCentrum! It was great to learn about Ewing Sarcoma organoids and how to use them as a tool to test new immunotherapies! Thanks to all the team, specilly to Elisabetta Liuzzi and Karin Sanders #ewingsarcoma #organoids 👩🏼‍🔬

Que bien poder ser participe de este proyecto! Gracias Fundación Fero Fundación Aladina por el apoyo! Seguimos! 👩🏼‍🔬💪🏿

From Barcelona to Milan ✈️ Proud of our IJC delegation attending #EHA2025! 👏 European Hematology Association

¡Avances en inmunoterapia para la leucemia infantil! Una nueva inmunoterapia para la leucemia infantil más frecuente demuestra su eficacia en modelos animales ✳️Enhorabuena al Dr Luis Álvarez-Vallina y equipos Hospital Universitario 12 de Octubre CNIO Stop Cancer Josep Carreras Leukaemia Research Institute (IJC)

📢 Big news from #EHA2025! Mercedes Guerrero (Menendez Lab) has been awarded an European Hematology Association Research Mobility Grant ✈️🌍 to join the Wellcome Sanger Institute Wellcome Genome Campus in #Cambridge for her PhD stay🔬 An incredible opportunity to push forward her research in blood cancers 👏